Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic (Centre Daily Times)
Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug application (IND) for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ...

Akorn, Inc. Announces FDA Approval Of Diclofenac Sodium Ophthalmic Solution 0.1% (Medical News Today)
Akorn, Inc. (NASDAQ: AKRX) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Akorn's Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Ophthalmic Solution, 0.1%. Diclofenac Sodium Ophthalmic Solution is a non-steroidal anti-inflammatory agent used to treat cataract and refractive surgery patients.